JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
这页已由机器翻译。其他页面可能仍然显示为英文。 View in English

与阿洛普里诺尔相比,费布可斯塔特在痛风患者中的长期心血管安全性 (FAST):多中心,前性,随机化,开放性,非劣势性试验

  • 0MEMO Research, Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
Lancet +

|

2020年十一月12日

在PubMed上查看摘要

概括

此摘要是机器生成的。

相关概念视频

Bioavailability Study Design: Healthy Subjects Versus Patients 01:15

65

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents 01:24

1.0K

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Bioequivalence studies: Biowaivers 01:13

96

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Bioavailability Study Design: Absolute Versus Relative Bioavailability 01:27

153

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...

Bioavailability Study Design: Single Versus Multiple Dose Studies 01:11

94

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence 01:22

101

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...